Geron Corporation $GERN Stake Lifted by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. raised its stake in Geron Corporation (NASDAQ:GERN) by 83.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,223,550 shares of the biopharmaceutical company’s stock after acquiring an additional 1,009,930 shares during the quarter. Nan Fung Trinity HK Ltd.’s holdings in Geron were worth $2,735,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Hsbc Holdings PLC purchased a new stake in Geron in the 2nd quarter worth approximately $25,000. LCM Capital Management Inc acquired a new stake in shares of Geron during the 3rd quarter worth approximately $25,000. GTS Securities LLC grew its stake in shares of Geron by 71.6% during the 2nd quarter. GTS Securities LLC now owns 23,772 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 9,921 shares during the period. M Holdings Securities Inc. purchased a new position in shares of Geron during the 3rd quarter valued at approximately $34,000. Finally, OneDigital Investment Advisors LLC purchased a new position in shares of Geron during the 2nd quarter valued at approximately $38,000. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Price Performance

Shares of Geron stock opened at $0.99 on Friday. The company has a quick ratio of 4.61, a current ratio of 6.31 and a debt-to-equity ratio of 0.53. Geron Corporation has a twelve month low of $0.84 and a twelve month high of $2.01. The business has a 50-day moving average price of $1.19 and a 200 day moving average price of $1.41. The firm has a market cap of $640.37 million, a PE ratio of -12.42 and a beta of 0.62.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on GERN shares. Wedbush decreased their target price on shares of Geron to $5.00 and set an “outperform” rating for the company in a research note on Wednesday, October 28th. Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Finally, Needham & Company LLC dropped their price target on shares of Geron from $4.00 to $2.50 and set a “buy” rating on the stock in a research report on Wednesday, October 28th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Geron has a consensus rating of “Hold” and a consensus target price of $3.75.

About Geron

Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.